Filing Details
Candel Therapeutics, Inc. (NASDAQ:CADL) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:CADL
Candel Therapeutics, Inc. (CADL) Files Quarterly Report for Q0
Candel Therapeutics, Inc. (NASDAQ:CADL) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
At publication ·
What changed
Candel Therapeutics, Inc. (NASDAQ:CADL) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Candel Therapeutics, Inc. (NASDAQ: CADL) filed its quarterly report (Form 10-Q) with the SEC on August 13, 2026.
- The company's stock trades at $11.80 with a market capitalization of $355.8 million.
- The 10-Q filing includes unaudited financial statements and management commentary on business performance, though specific revenue figures were not disclosed in this summary.
Market Context
Candel Therapeutics, Inc.'s stock currently trades at $11.80 with a market capitalization of $355.8M.
The 10-Q provides Candel Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Candel Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CADL Stock Page
Frequently Asked Questions
Where can I read CADL's SEC filings?
Browse all filings on our CADL SEC filings page.
What types of SEC filings does Candel Therapeutics, Inc. file?
Public companies like Candel Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.